Euroz Hartleys Upgrades Botanix Pharmaceuticals' to Buy From Speculative Buy, Adjusts Price Target to AU$0.47 From AU$0.33

03:45 AM EDT, 07/02/2024 (MT Newswires) -- Euroz Hartleys Upgrades Botanix Pharmaceuticals' to Buy From Speculative Buy, Adjusts Price Target to AU$0.47 From AU$0.33 Price (AUD): $0.33, Change: $+0.01

MT NewswiresJul 2 03:45 ET

AU Evening Wrap: ASX 200 Rises 0.3%, Ends Week Up 0.9%

ASX 200 rises 0.3%, completing a positive week driven by gains in utility, energy, and health stocks.

Moomoo News AUJun 21 03:32 ET

Botanix Pharmaceuticals to Raise AU$70 Million via Institutional Placement

Botanix Pharmaceuticals (ASX:BOT) received firm commitments for a AU$70 million capital raising through an institutional placement, the clinical dermatology company said in a Friday filing with the Au

MT NewswiresJun 20 21:52 ET

Botanix Pharmaceuticals Secures US FDA Approval for Topical Medication

Botanix Pharmaceuticals (ASX:BOT) secured a new drug application approval from the US Food and Drug Administration for the Sofdra-branded topical medication (sofpironium) topical gel, 12.45%, accordin

MT NewswiresJun 19 20:07 ET

Botanix Pharmaceuticals Share Price on Watch Amid FDA News and 'Transformative Event'

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price will be one to watch closely this week.

The Motley FoolJun 19 20:03 ET

Botanix Isn't Sweating on FDA Approval for Sofdra

Clinical dermatology company, Botanix Pharmaceuticals (ASX:BOT) has submitted the last label materials to the US Food & Drug Administration (FDA) for the approval of Sofdra™ a pending prescription treatment for excessive underarm sweating.

The Market HeraldJun 11 19:49 ET